https://www.selleckchem.com/pr....oducts/eliglustat.ht
4%, but would increase to 63.6% if the 14 patients with historic peak inhibitor titer ≥100BU (and having phase 2 success rate of only 14.3%) were excluded. One patient developed repeated infection after IS treatment. Relapse occurred in 11.4% (4/35) patients with phase 2 success associated with rapid ITI dose reduction or irregular post-ITI FVIII prophylaxis. Our strategy reduced the cost from high-dose ITI by 74% to 90%. The use of low-dose ITI with or without immunosuppressants according to ITI prognostic risk(s) is a clinically an
Like
Comment
Share
